Business Context and Reporting Period
Company: Nextplat Corp (NXPL)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended September 30, 2025
Business Overview: Nextplat operates two primary segments: e-Commerce Operations (satellite communication services, equipment sales, and online storefronts) and Healthcare Operations (pharmacy services, 340B contract services, and data management). The company is a smaller reporting company and non-accelerated filer.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Net Revenue | $13,752 | $15,367 | $41,517 | $49,849 |
| Gross Profit | $2,730 | $3,558 | $9,076 | $14,279 |
| Gross Margin | 19.9% | 23.2% | 21.9% | 28.6% |
| Net Loss (Attributable to Nextplat) | $(2,185) | $(4,216) | $(5,317) | $(11,008) |
| Loss Per Share (Basic/Diluted) | $(0.08) | $(0.22) | $(0.20) | $(0.58) |
| Cash and Equivalents | $13,926 | $20,360 (End Q3 2024) | $13,926 | $26,307 (Start YTD 2024) |
| Working Capital | $18,846 | $23,270 | $18,846 | $21,800 |
| Total Debt (Notes Payable) | $1,159 | $1,412 | $1,159 | $1,412 |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 11% in Q3 and 17% YTD compared to the prior year. The decline was driven primarily by a 77% drop in Pharmacy 340B contract revenue ($1.9M decrease in Q3) due to clients transitioning to other partners or opening in-house pharmacies. Healthcare prescription volume also fell (96,000 prescriptions in Q3 2025 vs. 128,000 in Q3 2024).
- Expense Reduction: Operating expenses decreased significantly by 59% in Q3 and 59% YTD. This was largely due to the absence of a $3.7M goodwill impairment loss recorded in Q3 2024 and a $13.7M impairment loss in the prior YTD period. Additionally, professional fees and stock-based compensation declined.
- Margin Compression: Gross margins contracted in both segments. Healthcare margins dropped to 18.4% (from 21.5%) due to the loss of high-margin 340B contracts. e-Commerce margins fell to 23.7% (from 28.1%) due to the expiration of a favorable airtime contract and new costs effective January 2025.
- Litigation Settlement: The company recorded a $250,000 loss on settlement of litigation in Q3 2025 related to a former employee dispute, which was accrued as a subsequent event.
Guidance, Outlook, and Risks
- Liquidity: Management states that existing cash resources ($13.9M) are sufficient to support operations for the next 12 months. The company is implementing cost reduction measures and exploring strategic alternatives.
- Share Repurchase: The company has a $2.0M share repurchase program authorized in December 2024. Approximately $0.1M was repurchased in the first nine months of 2025, with $1.9M remaining.
- Key Risks:
- Trade Tariffs: Ongoing U.S./China trade tensions and tariffs pose a risk to the e-Commerce segment, particularly regarding the "Florida Sunshine" vitamin line and sales in China.
- Customer Concentration: Amazon accounts for approximately 33% of e-Commerce revenue. Healthcare operations rely heavily on one vendor (98% of purchases) and three major PBMs (63% of reimbursements).
- Internal Controls: A material weakness regarding inventory valuation identified in 2024 has been remediated as of September 30, 2025.
- Subsequent Events:
- Settlement of a former employee lawsuit for $150,000 cash and $100,000 in stock (accrued in Q3).
- Lease termination for Coconut Grove office space with an estimated $120,000 fee (not accrued as it occurred post-balance sheet).
- Extension of PIPE Warrants expiration date to December 2027.
Investor Verification Checklist
- Verify the sustainability of the 340B contract revenue decline and the timeline for replacing lost clients.
- Assess the impact of the new airtime contract costs on e-Commerce gross margins in future quarters.
- Monitor the status of the pending class action lawsuit (Weisberg v. Nextplat) regarding the RXMD merger.
- Review the company's strategy for the "Florida Sunshine" brand given the paused initiatives due to tariffs.
- Confirm the effectiveness of the remediated inventory valuation controls in upcoming filings.